Drugs / HX4
HX4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00606424 | Jan 2008 → Jan 2009 | head and neck cancer | Siemens Molecular Imaging | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01213030 Comparator | Jun 2009 → Jan 2010 | head and neck cancer, liver cancer, lung cancer | Siemens Molecular Imaging | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HX4 | “evaluate a hypoxia imaging agent, HX4, in patients with solitary tumors (i.e., locally advanced head and neck cancer)” NCT01213030 ↗ |
| Known as | [F-18] HX4 | “Drug: [F-18] HX4” NCT01213030 ↗ |
| Known as | F-HX4 | “F-HX4 is a novel positron emission tomography (PET) tracer for imaging hypoxia.” PMID 20948452 ↗ Dec 2010 |
| Modality | Diagnostic / imaging agent | “F-HX4 is a novel positron emission tomography (PET) tracer for imaging hypoxia.” PMID 20948452 ↗ Dec 2010 |